Ipriflavone Bone Loss Prevention Benefits Unsupported - JAMA Study
This article was originally published in The Tan Sheet
Executive Summary
Ipriflavone is ineffective in preventing reductions in bone mineral density or affecting bone metabolism and may be less safe than prescription drugs because it decreases white blood cells, European researchers report in the March 21 Journal of the American Medical Association.
You may also be interested in...
FDA "Courtesy" Letters Focus On Structure/Function, Health Claim Distinction
Three recent FDA "courtesy" letters target the distinction between dietary supplement structure/function statements and authorized health claims for osteoporosis and heart disease.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands